Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against Emerging Viral Variants
- Study demonstrated the use of immortalized B-cell libraries as a rapid and adaptable approach to therapeutic development against evolving viral threats
- Discovered 12 antibodies with potent neutralizing activity against multiple SARS-CoV-2 strains, including Delta and BA.5, through high-throughput B-cell screening
- Applied ex vivo directed evolution to B-cell clones to enhance antibody neutralizing breadth and potency against emerging infectious disease variants
Amsterdam, NLD – 9 September 2025 – Kling Bio, the function-first biotech harnessing proprietary B-cell technology to discover novel targets and antibodies across multiple disease areas, today announced the publication of a peer-reviewed study titled ‘Immune counter-evolution: Immortalized B cell clones can undergo ex vivo directed evolution to counteract viral escape’ in the high impact journal Frontiers in Immunology, validating the company’s proprietary primary B-cell platform technologies for rapidly developing adaptable antibody therapeutics against evolving viral threats.
